Login / Signup

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.

Lisa Aniek de JongJessie GroeneveldJelena StevanovicHarrie RilaRobert G TielemanMenno V HuismanMaarten J PostmaMarinus van Hulst
Published in: PloS one (2019)
Based on RCTs as well as RWD, we conclude that apixaban is generally cost-effective or even cost-saving (less costly and more effective) compared to VKA and other NOACs in the overall population of patients with atrial fibrillation.
Keyphrases
  • venous thromboembolism
  • atrial fibrillation
  • study protocol
  • clinical trial
  • phase iii
  • oral anticoagulants
  • phase ii
  • randomized controlled trial